<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22702">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811250</url>
  </required_header>
  <id_info>
    <org_study_id>2009-556</org_study_id>
    <nct_id>NCT02811250</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiotherapy for Renal Cancers</brief_title>
  <acronym>RSR-1</acronym>
  <official_title>Stereotactic Radiotherapy for Renal Cancers: Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotactic radiotherapy is a technique that allows the delivery of a high dose of
      radiation over few fractions (3-6) with great precision. It thus allows &quot;tumor ablation&quot; and
      optimal preservation of healthy tissues. Initially developed in small-sized (&lt;5 cm) lung
      cancers this technique it gives results very close and or even equivalent to those of
      surgery.

      Stereotactic radiotherapy of brain metastases of renal cancers has shown that high doses of
      radiation allows local control in 90 to 98% of cases. A study conducted in Sweden (Wersall
      et al.) underline the interest to develop stereotactic radiotherapy in primary renal tumors.
      In Cleveland (USA) two phase I studies are already underway.

      The investigators propose to develop a phase I study for tumors of less than 4 cm. As found
      in lung cancers, stereotactic radiotherapy can provide a non-invasive, painless and rapid (4
      to 5 fractions) method for the treatment of renal cancers with a high rate of local control.

      The primary objective is to define the maximal tolerated dose for one fraction in
      stereotactic mode of renal tumors ≤ 4 cm in length using an a four-step dose increase:

        -  Step 1: 4 x 8 Gy.

        -  Step 2: 5 x 8 Gy.

        -  Step 3: 4 x 10 Gy.

        -  Step 4: 4 x 12 Gy.

      The patients will be followed during treatment with evaluation of acute toxicities before
      each session, then at 15 days, 6 weeks, 3 months, 9 months, 12 months, and then every 6
      months for a total duration of 5 years after treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of grade ≥ 4 toxicity</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>The primary outcome is the occurrence of grade ≥ 4 toxicity according to CTCAE version 4 (Common Terminology Criteria for Adverse Events) during treatment and in the 3 months after end of treatment .</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Renal Cancer</condition>
  <arm_group>
    <arm_group_label>Stereotactic radiotherapy 4 x 8 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receive 4 stereotactic radiotherapy sessions with a dose of 8 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic radiotherapy 5 x 8 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receive 5 stereotactic radiotherapy sessions with a dose of 8 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic radiotherapy 4 x 10 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receive 4 stereotactic radiotherapy sessions with a dose of 10 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic radiotherapy 4 x 12 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receive 4 stereotactic radiotherapy sessions with a dose of 12 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiotherapy 4 x 8 Gy</intervention_name>
    <arm_group_label>Stereotactic radiotherapy 4 x 8 Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiotherapy 5 x 8 Gy</intervention_name>
    <arm_group_label>Stereotactic radiotherapy 5 x 8 Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiotherapy 4 x 10 Gy</intervention_name>
    <arm_group_label>Stereotactic radiotherapy 4 x 10 Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiotherapy 4 x 12 Gy</intervention_name>
    <arm_group_label>Stereotactic radiotherapy 4 x 12 Gy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged over 75 years with an operable renal tumor or patient with inoperable
             renal tumor irrespective of age, or patient with metastatic renal tumor and
             indication for nephrectomy.

          -  Histologically-confirmed Renal carcinoma less than or equal to 4 cm

          -  Tumor that is visible and measureable on abdominal scanner and/or MRI (Magnetic
             Resonance Imaging)

          -  Karnofsky performance status ≥ 60%

        Exclusion Criteria:

          -  Patient with only one kidney and renal cancer

          -  Patient not able to cooperate during treatment

          -  Previous history of abdominal radiation therapy

          -  Tumor having infiltrated the renal pelvis

          -  Polycystic kidney disease

          -  Previous history of intestinal inflammatory disease such as ulcerative colitis or
             Crohn's disease

          -  Renal insufficiency (creatinine clearance &lt;30 ml/mm evaluated by DTPA
             (diethylenetriamine pentaacetic acid ) scintigraphy)

          -  Uncontrolled hypertension (SBP(systolic blood pressure) above 160 mmHg DBP(diastolic
             blood pressure) above 100 mmHg with antihypertensive treatment)

          -  Non primary lesions (benign lesions such as angiomyolipoma, renal metastases,…)

          -  Antineoplastic and/or antiangiogenic treatment in the month preceding radiotherapy

          -  Progressive cancer other than renal cancer at time of inclusion with the exception of
             in situ cervical carcinomas, basal cell carcinoma of the skin, and non-metastatic
             prostate cancer controlled without hormone therapy

          -  Participation in another ongoing study that may interfere with the present study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier CHAPET, MD</last_name>
    <phone>04 78 86 42 59</phone>
    <phone_ext>+33</phone_ext>
    <email>olivier.chapet@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sonya GAUDIOZ</last_name>
    <phone>4 78 86 42 62</phone>
    <phone_ext>+33</phone_ext>
    <email>sonia.gaudioz@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Radiothérapie - Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles CREHANGE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gilles CREHANGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie-Radiothérapie - Centre Hospitalier Lyon Sud - HCL</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CHAPET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier CHAPE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 29, 2016</lastchanged_date>
  <firstreceived_date>June 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal cancer</keyword>
  <keyword>Stereotactic radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
